Verastem Stock Surges Over 50% on Positive Pancreatic Cancer Drug Data
Verastem (VSTM) stock plummeted by 62% following the release of clinical trial data for its metastatic pancreatic cancer treatment, which revealed serious adverse events in 12 patients, including 11 with grade ≥3 events. Despite initial positive results, the safety concerns led to heavy trading and a significant drop in stock value.
